ReviewGut microbes
Exploring substrate-microbe interactions: a metabiotic approach toward developing targeted synbiotic compositions.
Review in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Del immune V and microbiome restructuring in colorectal cancer surgery: a randomized double blind placebo controlled trial.Frontiers in cellular and infection microbiology · 2026Trial
- Novel probiotic preparation withMicrobiology spectrum · 2024Trial
- SynbioticNutrients · 2024Trial
- Microbiota-Mediator-Host Signaling Networks in Metabolic Syndrome: From Mechanistic Insights to Therapeutic Targeting.Microorganisms · 2026Review
- Gut microbiota and renal fibrosis: novel mechanistic insights and therapeutic potential.Acta pharmacologica Sinica · 2026Review
- Synergistic synbiotic therapies for ulcerative colitis: mechanistic insights from multi-targeted pathways in animal models.Inflammopharmacology · 2026Review
- Article
- Bioengineering Interventions to Enhance the Capacity of the Gut Microbiota in Controlling Food Allergies.Life (Basel, Switzerland) · 2026Review
- Polyphenols Bioactive Metabolites, and Their Anti-Biofilm and Neuroprotective Potential.Foods (Basel, Switzerland) · 2025Review
- Medicinal Plants for a Healthy Gut Microbiome: Scientific Insights into Modern Herbal Applications.International journal of molecular sciences · 2025Review
- (Poly)phenol-gut microbiota interactions and their impact on human health.Current opinion in clinical nutrition and metabolic care · 2025Review
- Gut Microbiome Modulation and Health Benefits of a Novel Fucoidan Extract fromMicroorganisms · 2025Article
- Article
- Targeting gut microbiota for diabetic nephropathy treatment: probiotics, dietary interventions, and fecal microbiota transplantation.Frontiers in endocrinology · 2025Review
- Polyphenols and Microbiota Modulation: Insights from Swine and Other Animal Models for Human Therapeutic Strategies.Molecules (Basel, Switzerland) · 2024Review
- Modulation of gut microbiome in response to the combination ofFrontiers in nutrition · 2024Article
- Omics approaches in understanding the benefits of plant-microbe interactions.Frontiers in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota is an important modulator of human health and contributes to high inter-individual variation in response to food and pharmaceutical ingredients. The clinical outcomes of interventions with prebiotics, probiotics, and synbiotics have been mixed and often unpredictable, arguing for novel approaches for developing microbiome-targeted therapeutics. Here, we review how the gut microbiota determines the fate of and individual responses to dietary and xenobiotic compounds via its immense metabolic potential. We highlight that microbial metabolites play a crucial role as targetable mediators in the microbiota-host health relationship. With this in mind, we expand the concept of synbiotics beyond prebiotics' role in facilitating growth and engraftment of probiotics, by focusing on microbial metabolism as a vital mode of action thereof. Consequently, we discuss synbiotic compositions that enable the guided metabolism of dietary or co-formulated ingredients by specific microbes leading to target molecules with beneficial functions. A workflow to develop novel synbiotics is presented, including the selection of promising target metabolites (e.g. equol, urolithin A, spermidine, indole-3 derivatives), identification of suitable substrates and producer strains applying bioinformatic tools, gut models, and eventually human trials.In conclusion, we propose that discovering and enabling specific substrate-microbe interactions is a valuable strategy to rationally design synbiotics that could establish a new category of hybrid nutra-/pharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.